GillespieG., MutisT., SchramaE., KampJ., EsendamB., FalkenburgJ.F., GouldemyE., MossP.: HLA class I-minor histocompatibility antigen tetramere select cytotoxic T cells with high avidity to the natural ligand.Hematol J, 1: 403–410, 2000.
2.
KawakamiY., RosenbergS.A.: Human tumor antigens recognized by T-cells.Immunol Res, 6: 313–339, 1997.
3.
LeeP.P., YeeC., SavageP.A.: Characterization of circulating T cells specific for tumor associated antigens in melanoma patients.Nature Med, 5: 677–685, 1999.
4.
UenoN.T., RondonG., MirzaN.Q.: Allogeneic peripheral-blood progenitor-cell transplantation for poor risk patients with metastatic breast cancer.J Clin Oncol, 16: 986–993, 1998.
5.
BayJ.O., ChoufiB., PomelC.: Potential allogeneic graft-versus-tumor effect in a patient with ovarian cancer.Bone Marrow Transplant, 25: 681–682, 2000.
6.
GiraltS., EsteyE., AlbitarM.: Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.Blood, 89: 4531–4536, 1997.
7.
KhouriI.F., KeatingM., KorblingM.: Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies.J Clin Oncol, 16: 2817–2824, 1998.
8.
SlavinS., NaglerA., NaparstekE.: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.Blood, 91: 756–763, 1998.
9.
GiraltS., ThallP.F., KhouriI.: Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.Blood, 97: 631–637, 2001.
10.
MCSweeneyP.A., NiederwieserD., ShizuruJ A.: Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.Blood, 97: 3390–3400, 2001.
11.
SykesM., PrefferF., McAfeeS.: Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation.Lancet, 353: 1755–1759, 1999.
12.
KottaridisP.D., MilliganD.W., ChopraR.: In vivo Campath-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.Blood, 96: 2419–2425, 2000.
13.
ChildsR., ClaveE., ContentinN.: Engraftment kinectis after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T cell chimerism precedes alloimmune responses.Blood, 94: 3234–3241, 1999.
ZetterquistH., HentschkeP., ThorneA.A graft-versuscolonic cancer effect of allogeneic stem cell transplantation.Bone Marrow Transplant, 28: 1161–1166, 2001.
16.
MoscardoF., MartinezJ.A., SanzG.F.: Graft-versus-tumour effect in non-small-cell lung cancer after allogeneic peripheral blood stem cell transplantation.Br J Haematol, 111: 708–710, 2000.
17.
BregniM., DoderoA., PeccatoriJ.: Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer.Blood, 99: 4234–4236, 2002.
